Literature DB >> 8290254

Structural inferences of the ETS1 DNA-binding domain determined by mutational analysis.

G Mavrothalassitis1, R J Fisher, F Smyth, D K Watson, T S Papas.   

Abstract

The ets family of transcription factors is characterized by a conserved region that harbors the DNA-binding activity. We performed extensive deletion and mutational analyses, as well as DNA-peptide interaction studies necessary to identify the determinants of the DNA-binding activity of the ETS1 oncoprotein. We found that amino acids beyond the 85 amino acid conserved region are required in order to afford maximum DNA-binding activity in a heterologous system. Mutation throughout the binding domain can have a detrimental effect on binding activity, indicating that proper folding of the entire domain is necessary for DNA binding. A peptide, as small as 37 residues (K37N), derived from the basic region of the ETS1 binding domain, is sufficient to exhibit sequence-specific DNA recognition. Total randomization of Lysine 379, Lysine 381 and Arginine 391 within this region fails to provide functional substitutions, indicating that these specific amino acids within the basic region are required for binding. Transactivation activity of the ETS1 proteins bearing mutations was consistent with their DNA-binding activity, indicating that the primary (if not only) function of this domain is to provide sequence-specific DNA recognition activity. Our mutational analysis, as well as modeling predictions, lead us to propose a helix-turn-helix structure for the basic region of the ETS1 binding domain that is able to interact directly with DNA. We also propose that the hydrophobic alpha-helical region, surrounding tryptophan 338, is fundamental for proper protein folding and functioning of the ets binding domain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8290254

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

1.  ETS1 suppresses tumorigenicity of human colon cancer cells.

Authors:  H Suzuki; V Romano-Spica; T S Papas; N K Bhat
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

2.  Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif.

Authors:  L W Donaldson; J M Petersen; B J Graves; L P McIntosh
Journal:  EMBO J       Date:  1996-01-02       Impact factor: 11.598

3.  The secondary structure of the ets domain of human Fli-1 resembles that of the helix-turn-helix DNA-binding motif of the Escherichia coli catabolite gene activator protein.

Authors:  H Liang; E T Olejniczak; X Mao; D G Nettesheim; L Yu; C B Thompson; S W Fesik
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

4.  A residue of the ETS domain mutated in the v-ets oncogene is essential for the DNA-binding and transactivating properties of the ETS-1 and ETS-2 proteins.

Authors:  N Soudant; O Albagli; P Dhordain; A Flourens; D Stéhelin; D Leprince
Journal:  Nucleic Acids Res       Date:  1994-09-25       Impact factor: 16.971

5.  ERF: an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell cycle and mitogenic stimulation.

Authors:  D N Sgouras; M A Athanasiou; G J Beal; R J Fisher; D G Blair; G J Mavrothalassitis
Journal:  EMBO J       Date:  1995-10-02       Impact factor: 11.598

6.  Ets-1 confers cranial features on neural crest delamination.

Authors:  Eric Théveneau; Jean-Loup Duband; Muriel Altabef
Journal:  PLoS One       Date:  2007-11-07       Impact factor: 3.240

7.  Overexpression of the Ets-1 transcription factor in human breast cancer.

Authors:  Y Buggy; T M Maguire; G McGreal; E McDermott; A D K Hill; N O'Higgins; M J Duffy
Journal:  Br J Cancer       Date:  2004-10-04       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.